2.09
price up icon1.23%   0.05
after-market アフターアワーズ: 2.09
loading
前日終値:
$2.04
開ける:
$2.05
24時間の取引高:
311.76K
Relative Volume:
2.27
時価総額:
$119.53M
収益:
-
当期純損益:
$-46.12M
株価収益率:
-2.7986
EPS:
-0.7468
ネットキャッシュフロー:
$-41.02M
1週間 パフォーマンス:
+1.72%
1か月 パフォーマンス:
+34.97%
6か月 パフォーマンス:
+35.86%
1年 パフォーマンス:
+41.44%
1日の値動き範囲:
Value
$1.97
$2.14
1週間の範囲:
Value
$1.51
$2.37
52週間の値動き範囲:
Value
$1.165
$2.44

Inflarx N V Stock (IFRX) Company Profile

Name
名前
Inflarx N V
Name
セクター
Healthcare (1195)
Name
電話
-
Name
住所
-
Name
職員
66
Name
Twitter
Name
次回の収益日
2024-11-08
Name
最新のSEC提出書
Name
IFRX's Discussions on Twitter

IFRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IFRX 2.09 119.53M 0 -46.12M -41.02M -0.7468
VRTX 450.34 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.15 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.68 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.25 24.89B 3.30B -501.07M 1.03B 11.54

Inflarx N V Stock (IFRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-04-05 アップグレード Guggenheim Neutral → Buy
2022-02-28 ダウングレード Guggenheim Buy → Neutral
2021-10-28 アップグレード Raymond James Outperform → Strong Buy
2021-03-11 アップグレード Guggenheim Neutral → Buy
2020-11-06 アップグレード SVB Leerink Mkt Perform → Outperform
2020-10-08 開始されました H.C. Wainwright Buy
2020-06-17 開始されました BTIG Research Buy
2020-04-30 アップグレード Raymond James Mkt Perform → Outperform
2019-06-05 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-06-05 ダウングレード Guggenheim Buy → Neutral
2019-06-05 ダウングレード JP Morgan Overweight → Underweight
2019-06-05 ダウングレード Robert W. Baird Outperform → Neutral
2019-06-05 ダウングレード SunTrust Buy → Hold
2019-01-29 開始されました Robert W. Baird Outperform
2018-12-10 開始されました Credit Suisse Outperform
2018-07-13 開始されました BMO Capital Markets Outperform
2018-06-28 開始されました Raymond James Outperform
2018-06-28 開始されました SunTrust Buy
2018-02-08 開始されました B. Riley FBR, Inc. Buy
すべてを表示

Inflarx N V (IFRX) 最新ニュース

pulisher
Nov 19, 2024

10 Best German Stocks To Buy Now - Insider Monkey

Nov 19, 2024
pulisher
Nov 19, 2024

Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now? - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

Lucid Capital sets Inflarx NV Buy stock rating on clinical trial potential - Investing.com

Nov 19, 2024
pulisher
Nov 15, 2024

InflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatment - MSN

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx’s GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - ழ தொலைக்காட்சி

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx Receives Positive CHMP Opinion for GOHIBIC® - GlobeNewswire

Nov 15, 2024
pulisher
Nov 15, 2024

InflaRx's GOHIBIC Secures Key EU Backing for COVID ARDS Treatment After 24% Mortality Reduction | IFRX Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

FY2024 EPS Estimates for InflaRx Cut by Leerink Partnrs - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn

Nov 14, 2024
pulisher
Nov 14, 2024

FY2024 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

FY2024 EPS Estimates for InflaRx Reduced by Leerink Partnrs - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Prenetics Global And 2 Other US Penny Stocks To Watch - Simply Wall St

Nov 13, 2024
pulisher
Nov 12, 2024

InflaRx Reports Q3 2024 Financial Results and Progress - Yahoo Finance

Nov 12, 2024
pulisher
Nov 11, 2024

InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate - Yahoo Finance

Nov 10, 2024
pulisher
Nov 08, 2024

InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

InflaRx Reports Rising Revenue Amidst Significant Losses - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 08, 2024
pulisher
Nov 07, 2024

InflaRx (IFRX) to Release Earnings on Friday - Defense World

Nov 07, 2024
pulisher
Nov 01, 2024

InflaRx (IFRX) Set to Announce Quarterly Earnings on Friday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

InflaRx to Report Third Quarter 2024 Financial Results on - GlobeNewswire

Oct 31, 2024
pulisher
Oct 22, 2024

Critical Review: PDS Biotechnology (NASDAQ:PDSB) & InflaRx (NASDAQ:IFRX) - Defense World

Oct 22, 2024
pulisher
Oct 14, 2024

InflaRx (NASDAQ:IFRX) Sees Significant Increase in Short Interest - MarketBeat

Oct 14, 2024
pulisher
Sep 26, 2024

InflaRx shares maintain Buy rating from H.C. Wainwright on Gohibic trial analysis - Investing.com

Sep 26, 2024
pulisher
Sep 25, 2024

InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx reports promising HS treatment results at EADV Congress - Investing.com India

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx presents e-poster presentation of post hoc analysis of SHINE study - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx Presents Post Hoc Analysis of SHINE Trial of - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 - EIN News

Sep 25, 2024
pulisher
Sep 05, 2024

InflaRx Announces Participation in September Investor Events - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 05, 2024

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 04, 2024

InflaRx (NASDAQ:IFRX) Stock Price Up 1.3% - MarketBeat

Sep 04, 2024
pulisher
Sep 04, 2024

InflaRx (NASDAQ:IFRX) Shares Up 1.3% - Defense World

Sep 04, 2024
pulisher
Sep 03, 2024

InflaRx reports promising data on oral C5aR inhibitor INF904 - Investing.com

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human - EIN News

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx reports promising data on oral C5aR inhibitor INF904 By Investing.com - Investing.com UK

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx presents new preclinical findings for INF904 - TipRanks

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx Presents New Preclinical Findings for INF904 at the - GlobeNewswire

Sep 03, 2024
pulisher
Sep 01, 2024

InflaRx (NASDAQ:IFRX) Short Interest Down 9.2% in August - MarketBeat

Sep 01, 2024
pulisher
Aug 13, 2024

Short Interest in InflaRx (NASDAQ:IFRX) Rises By 281.4% - MarketBeat

Aug 13, 2024
pulisher
Aug 08, 2024

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx N.V. Reports Mid-Year Financial Results - TipRanks

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx reports Q2 EPS (24c), consensus (22c) - TipRanks

Aug 08, 2024
pulisher
Aug 07, 2024

InflaRx (IFRX) Set to Announce Earnings on Thursday - Defense World

Aug 07, 2024
pulisher
Aug 02, 2024

InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat

Aug 02, 2024

Inflarx N V (IFRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):